Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Certification | 2 | 2017 | 49 | 0.700 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 17 | 0.690 |
Why?
|
| General Surgery | 2 | 2017 | 49 | 0.680 |
Why?
|
| Test Taking Skills | 1 | 2017 | 1 | 0.590 |
Why?
|
| Internship and Residency | 2 | 2017 | 213 | 0.560 |
Why?
|
| Clinical Competence | 1 | 2017 | 230 | 0.500 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 126 | 0.420 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 18 | 0.390 |
Why?
|
| Organ Transplantation | 4 | 2021 | 37 | 0.370 |
Why?
|
| Liver Transplantation | 4 | 2014 | 79 | 0.350 |
Why?
|
| Tissue and Organ Procurement | 4 | 2009 | 34 | 0.270 |
Why?
|
| Educational Measurement | 2 | 2017 | 58 | 0.270 |
Why?
|
| Graft Rejection | 4 | 2009 | 75 | 0.260 |
Why?
|
| Aneurysm | 1 | 2022 | 11 | 0.210 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 10 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 14 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 47 | 0.200 |
Why?
|
| Renal Dialysis | 3 | 2022 | 110 | 0.190 |
Why?
|
| Graft Survival | 6 | 2014 | 98 | 0.190 |
Why?
|
| Surgical Instruments | 1 | 2020 | 25 | 0.190 |
Why?
|
| Adult | 15 | 2020 | 8748 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2020 | 70 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2020 | 141 | 0.170 |
Why?
|
| Humans | 22 | 2022 | 29851 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3325 | 0.150 |
Why?
|
| Intestines | 2 | 2008 | 108 | 0.150 |
Why?
|
| Male | 16 | 2020 | 15871 | 0.150 |
Why?
|
| Simulation Training | 1 | 2017 | 34 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2022 | 3561 | 0.140 |
Why?
|
| United States | 4 | 2017 | 2346 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 135 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 81 | 0.140 |
Why?
|
| Female | 15 | 2020 | 16430 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 142 | 0.130 |
Why?
|
| Curriculum | 1 | 2017 | 161 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 158 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 60 | 0.120 |
Why?
|
| Time Factors | 5 | 2022 | 1641 | 0.120 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 3 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 19 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 29 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 42 | 0.110 |
Why?
|
| Middle Aged | 13 | 2020 | 9963 | 0.110 |
Why?
|
| Stents | 1 | 2013 | 76 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 158 | 0.110 |
Why?
|
| Vascular Patency | 2 | 2022 | 14 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 279 | 0.100 |
Why?
|
| Liver | 2 | 2009 | 175 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 135 | 0.100 |
Why?
|
| Child | 6 | 2009 | 1379 | 0.090 |
Why?
|
| Stomach | 1 | 2009 | 18 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 27 | 0.090 |
Why?
|
| Living Donors | 1 | 2009 | 7 | 0.080 |
Why?
|
| Gastric Fistula | 1 | 2009 | 3 | 0.080 |
Why?
|
| Leucine | 1 | 2009 | 15 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 7 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 2009 | 12 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2009 | 14 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 28 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 4 | 0.080 |
Why?
|
| Pancreatectomy | 1 | 2008 | 12 | 0.080 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 20 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 16 | 0.080 |
Why?
|
| Colon | 1 | 2009 | 149 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 4 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 20 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 70 | 0.080 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 12 | 0.080 |
Why?
|
| Lung Transplantation | 1 | 2007 | 18 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 9621 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2008 | 143 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 73 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 140 | 0.070 |
Why?
|
| Adolescent | 5 | 2009 | 2334 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 177 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 2 | 2002 | 151 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 310 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 34 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 654 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2014 | 15 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2002 | 53 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 24 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 11 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 22 | 0.050 |
Why?
|
| Carcinoma | 1 | 2002 | 59 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 46 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 23 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 34 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 35 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 194 | 0.050 |
Why?
|
| Risk Factors | 2 | 2022 | 2467 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 143 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 176 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 759 | 0.040 |
Why?
|
| Insulin | 2 | 2008 | 92 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 957 | 0.040 |
Why?
|
| Infant | 2 | 2008 | 542 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 4930 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 149 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1859 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 508 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 1969 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 332 | 0.030 |
Why?
|
| Probability | 2 | 2002 | 94 | 0.030 |
Why?
|
| Reoperation | 2 | 2008 | 927 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 364 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 494 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1187 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 34 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 16 | 0.020 |
Why?
|
| Prognosis | 2 | 2002 | 874 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 54 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 1 | 0.020 |
Why?
|
| Procaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2008 | 5 | 0.020 |
Why?
|
| Amylases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 245 | 0.020 |
Why?
|
| Mannitol | 1 | 2008 | 12 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 5 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 32 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 46 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 12 | 0.020 |
Why?
|
| Indiana | 1 | 2008 | 17 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 38 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 54 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 60 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 3 | 0.020 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 3 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 112 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 28 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 362 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 57 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 239 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 270 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 803 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 181 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 685 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1126 | 0.020 |
Why?
|
| Medical Records | 1 | 2002 | 33 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2002 | 25 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 24 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 51 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 58 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 96 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 78 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 327 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 232 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 332 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 376 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 532 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 558 | 0.010 |
Why?
|